Prevalence and Treatment Outcome of Drug-resistant Mycobacterium tuberculosis among People Living with Human Immunodeficiency Virus in Two Hospitals of the Southwest Region - Cameroon

Read full text Summarise with VIRAT
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Benjamin D. Thumamo Pokam1,2*, Forbi Catherine Ngum3, Yangkam Yhiler Nchawa3, Guemdjom Wabo Prisca2,4, Cecile Ingrid Djuikoue2,5 Departments of 1Medical Laboratory Sciences and 4Public Health, Faculty of Health Sciences, University of Buea, 3Department of Public Health and Administration, School of Health Sciences, Biaka University Institute of Buea, Buea, 2Central African Network for the Integrated Control of Antimicrobial Resistance, Bafoussam, Cameroon, 5Department of Veterinary Management of Animal Resources, Faculty of Veterinary Medicine, University of Liège, Liège, Belgium Background: Tuberculosis (TB) is a leading cause of morbidity and mortality among people living with human immunodeficiency virus (PLWHIV), particularly in sub-Saharan Africa. The emergence of multidrug-resistant/rifampicin-resistant TB (RR-TB) poses a serious public health threat by complicating treatment and increasing the risk of poor outcomes. This study aimed to determine the prevalence, associated factors, and treatment outcomes of RR-TB among PLWHIV in the Southwest Region of Cameroon, a high TB/human immunodeficiency virus burden country, from 2020 to 2024. Methods: A retrospective hospital-based study was conducted at the Regional Hospital Limbe (RHL) and Kumba Regional Hospital Annex (KRHA). Medical records of 322 PLWHIV diagnosed with TB between 2020 and 2024 were reviewed. Data were analyzed using the Statistical Package for the Social Sciences (SPSS, IBM, Chicago - United States). Descriptive statistics summarized demographic and clinical characteristics, and Chi-square or Fisher’s exact tests were used to examine associations, with statistical significance set at P < 0.05. Results: Of the 322 patients’ files reviewed, the mean age was 39.7 ± 12.5 years; 172 (53.4%) were female, and 242 (75.2%) resided in urban areas. Pulmonary TB accounted for 252 (78.3%) of cases. Nearly all patients (320 [99.4%]) were on antiretroviral therapy during the course of TB treatment. The prevalence of RR-TB was 4.0%, and was slightly higher at KRHA (5.6% [7/124]) compared to RHL (3.0% [6/198]). Prior TB treatment was significantly associated with drug resistance (P < 0.001), while no significant association was found with other demographic or clinical factors. Among the total number of RR-TB patients, 11/13 (84.6%) were cured, and 2/13 (15.4%) died. Treatment success was highest in 2020, with all 6 patients (100%) cured, while the only patient treated in 2024 died. Conclusion: RR-TB among PLWHIV in the Southwest Region of Cameroon is relatively low, with favorable treatment outcomes. Previous TB treatment was the only factor significantly associated with resistance, highlighting the need for improved surveillance and tailored interventions for such patients. Keywords: Cameroon, human immunodeficiency virus co-infection, rifampicin resistance, southwest region, treatment outcome, tuberculosis Conflicts of interest There are no conflicts of interest

Fields of Study & Subjects

Tuberculosis Research and Epidemiology Infectious Diseases and Tuberculosis Diagnosis and treatment of tuberculosis

Publication details

Journal / source
International Journal of Mycobacteriology
Volume
15
Issue
Abstract Supplement
Pages
S35–S35
Publication date
1 March 2026
Language
EN